Tranexamic acid powder

This synthetic derivative of lysine, known as Tranexamic acid powder, serves as an antifibrinolytic in the prevention and treatment of significant bleeding. It operates similarly to aminocaproic acid but boasts approximately ten times the potency. The compound was initially patented in 1957 and received approval for use in the United States in 1986.